Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA White Oak Construction Nears Completion, But Some Plans On Hold

This article was originally published in The Tan Sheet

Executive Summary

The biodefense complex would remain on schedule for fiscal 2014 completion, but communications and logistical buildings included in the master plan would be on hold. FDA tells Congress the sprawling campus must receive necessary operational funds as more employees move there.

You may also be interested in...



Biosimilars, Generic Programs Leave Little Room For Other New FDA Drug Initiatives In FY ‘13

Proposed and existing user fees would fund 44% of the $4.5 billion FDA FY 2013 spending plan. User fees are projected at $20 million for biosimilars and $229 million for generic drugs.

FDA To Spend PDUFA Reserves To Fund Safety Officers, Personnel Moves

Agency will spend more than 78% of $150.6 million fund by the end of FY 2012 to move CBER to White Oak and pay for new drug safety personnel.

President's Budget Proposal Points To Expanding FDA User Fees

President Obama's fiscal 2012 budget request concurs with FDA in recommending that Congress expand the type of user fees that industry pays for food safety enforcement reform.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS105589

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel